Positive results for the PACIFIC clinical trial evaluating the novel precision medicine, Imfinzi (durvalumab) as sequential treatment in patients with Stage III non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy have been reported.1

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease, and ew treatments are needed. Precision medicine continues to impact the lives of lung cancer patients with research into genomics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match an individual’s unique cancers genetic profile. As a result, patients with lung cancer now typically re­ceive molecular testing that guides their physicians in determining which therapies are more likely to improve their chances of survival while limiting the potential for adverse effects.

Stage III NSCLC represents approximately one third of NSCLC’s and was estimated to affect around 100,000 individuals worldwide.2   About half of these patients have cancers that cannot be removed by surgery.

About Imfinzi
Imfinzi (durvalumab) is a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the cancer’s immune-evading tactics and inducing an immune response against the cancer cells.

About PACIFIC Clinical Trial
The PACIFIC clinical evaluated Imfinzi as sequential treatment in patients with locally-advanced, unresectable, stage III NSCLC. Patients received placebo or sequential treatment with Imfinzi for up to 12 months if they had not progressed following standard platinum-based chemotherapy concurrent with radiation. A planned interim analysis conducted by an Independent Data Monitoring Committee concluded that the trial has already met one primary endpoint by showing a clinically-meaningful improvement in progression free survival. Additional trial result from the PACIFIC trial will be presented at a forthcoming medical meeting.

References:

  1. Kantar, other market research based on 2016 patient numbers; Globocan 2012. G7 countries include the US, Japan, Germany, the UK, France, Italy and Canada.

Copyright © 2017 CancerConnect. All Rights Reserved.